HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Closes Potential Food Additive Option In Warnings To Supplement Firms

Executive Summary

Six warnings to firms marketing products containing DMHA mark a change in the agency's supplement market oversight with explanation that non-dietary ingredients that have not been approved for use in food are deemed unsafe and are not allowed for use in supplements under an exemption for food additives Other three firms FDA warned were advised the ingredient phenibut found in their products also isn't eligible for use in supplements.

You may also be interested in...



DMHA Gets FDA Attention At Alternative Labs, CBD Noticed While There

Warning doesn't reference any noncompliant claims for CBD-labeled Green Roads, but FDA explains the basis for which it has stated for two years it could warn every firm marketing products that are labeled as or found containing CBD.

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

Innovo Incontinence Device Goes OTC In US, Labeled To Be Worn For 30 Minutes

Atlantic Therapeutics estimates that one in three women are incontinent, but 60% don’t ask their health care providers about treatment, a statistic that supports offering Innovo OTC less than two years after it launched Rx in the US.

Topics

UsernamePublicRestriction

Register

RS148732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel